Making it happen: the road to commercial scale cell therapy manufacturing

The long-term transformative potential of cell and gene therapies has become increasingly clear in recent years, and it is equally apparent that bringing innovative therapies to patients faces no shortage of roadblocks. Therefore, providing solutions to the challenges of manufacturing cell and gene therapies has never been so significant as an increasing number of products head towards commercialization. Key challenges include developing manufacturing processes that deliver a high-quality product with a reasonable cost of goods, which are also scalable to meet the changing demands throughout the full product life-cycle.

Watch this On Demand webinar to hear about the latest advances and technologies developed by Lonza for next-generation cell & gene therapy manufacturing, with real life examples and best practises, and gain insight into:

• Advanced technologies and platforms that enable processes for cell therapies which are robust, repeatable, and cost-efficient;
• Current approaches to commercial-scale manufacture of cell therapy products and the unique challenges and limitations of each;
• Transitioning cell therapy products from development through to GMP manufacturing and commercial success;
• Current manufacturing techniques for the generation of pluripotent stem cells.

The Lonza logo is a Lonza Ltd. Trademark

Yonatan Levinson

Senior Scientist, Allogeneic Bioreactor Platforms, Cell Therapy at Lonza Pharma & Biotech

Yoni Levinson is a Senior Scientist who joined Lonza in 2016 to lead the allogeneic cell therapy R&D group. Yoni’s group focuses on bioreactor technologies for cell therapy, as well as novel scaffolds and Process Analytical Technology. Prior to Lonza, Yoni worked in cell therapy process development around 3D bioreactors.

Thomas Richardson

Scientist II at Lonza Pharma & Biotech

Thomas Richardson is a Bioprocess Scientist in Cell Therapy Process Development, part of the Emerging Technologies Division of Lonza. He earned his PhD in Chemical Engineering from the University of Pittsburgh, where his dissertation work concentrated on the development of novel propagation techniques for the scalable culture of human pluripotent stem cells (hPSCs). In particular, he focused on the effect of biomaterial encapsulation on the pancreatic differentiation of hPSCs to support biomanufacturing of hPSC-derived insulin producing cells. At Lonza his work has focused on the development of GMP cell therapy processes with autologous and allogeneic cell sources and utilizing a myriad of devices such as multi-layered planar vessels and stirred-suspension bioreactors. His talk will provide an overview of some these exciting technologies as well as discuss the specific challenges faced in developing GMP manufacturing processes for cell-based therapies and how Lonza is addressing them.

Inbar Friedrich Ben-Nun

Senior Manager at Lonza

Dr. Inbar Friedrich Ben-Nun is a Sr. Manager in the Cell and Gene Therapy R&D at Lonza. Inbar obtained her PhD in Molecular and Structural Biochemistry at the Hebrew University of Jerusalem. As a postdoctoral fellow at the Scripps Research Institute, CA, she acquired extensive experience with pluripotent stem cells. Her work published in “Nature Methods” showed for the first time that stem cell research could be apply to save species from extinction.

Inbar has joined Lonza in 2011, and in her current role she leads a team that focuses on developing innovative solutions to enable stem cell-based therapies.

Watch now

SPEAKERS

Yonatan Levinson

Senior Scientist, Allogeneic Bioreactor Platforms, Cell Therapy at Lonza Pharma & Biotech

Thomas Richardson

Scientist II at Lonza Pharma & Biotech

Inbar Friedrich Ben-Nun

Senior Manager at Lonza

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 69

Days

Register

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe

29 May

in 40

Days

Register

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz

23 May

in 34

Days

Register

T cells from beginning to end: optimizing leukopak and drug product cryopreservation

Meredith Safford, ShaNelle Yelity

22 May

in 33

Days

Register

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes

21 May

in 32

Days

Register